A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Haywood’s analyst Gianluca Tucci reiterates their Buy rating on the shares of WELL Health Technologies Corp (WELL – Research Report), with a $8.00 price target.
According to TipRanks.com, Tucci is ranked #841 out of 8495 analysts.
WELL Health Technologies Corp has an analyst consensus of Strong Buy, with a price target consensus of C$8.34.
Based on WELL Health Technologies Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$169 million and GAAP net loss of C$14.36 million. In comparison, last year the company earned revenue of C$127 million and had a GAAP net loss of C$8.02 million.
WELL Health Technologies Corp is the owner and operator of a portfolio of Primary Hclinics delivering healthcare-related services It operates through below segments: Clinical services, Digital services, and others. It also engages in the Electronic Medical Records business that supports the digitization of clinics. Its objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.
The company’s shares closed last Thursday at C$4.64.
Read More on TSE:WELL:
